Daiichi Sankyo shakes up its R&D leadership, dispatching Junichi Koga to the US to run global ops
Two years after bringing out the budget ax and shaking up its global R&D group, Daiichi Sankyo is revamping the leadership of its research arm and shifting the center of gravity to the US. They’re also sharpening their focus on oncology at a time the pursuit of new cancer drugs has gripped most of the majors.
Out: Glenn Gormley, who took the R&D reins at Daiichi Sankyo in 2011 after a 20-year run at three big pharma groups: Merck, AstraZeneca and Novartis. He’ll stay on, though, as chairman of the board and special adviser to global CEO Joji Nakayama.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.